|
Previous Issues
Editorial Board: Abul K. Abbas, MD, University of California, San Francisco | Carla J. Greenbaum, MD, Benaroya Research Institute Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital | Holden T. Maecker, PhD, Stanford University
|
Highlights from Recent Literature
|
| Edited by Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital, Harvard Medical School |
Thymic Output Potential is Disparate Between Mice and Man
A Review of Den Braber I, et al. Maintenance of Peripheral Naïve T Cells is Sustained by Thymus Output in Mice but not Humans. Immunity 36; 288-297.
Reviewed by Christopher Borges and Laurence Turka, MD, Beth Israel Deaconess Medical Center and Harvard Medical School |
|
The CD8 T Cell Tolerant State can be Broken and Restored
A Review of Schietinger A, et al. Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State. Science 335; 723-727, 2012. Reviewed by Christopher Borges and Laurence Turka, MD, Beth Israel Deaconess Medical Center and Harvard Medical School |
|
How to Kill Malignant T Cell but not Normal Protective T Cells in Cutaneous Lymphoma Patients
A Review of Clark et al. Skin Effector Memory T Cells do not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients. Science Translational Medicine (2012) 4:117ra7. Reviewed by Andrew H. Lichtman, MD, PhD, Brigham and Women's Hospital. |
|
Cancer Exome Analysis Reveals a T Cell-dependent Mechanism of Cancer Immunoediting
A Review of Matsushita H, et al. Nature 2012;482:400-404.
Reviewed by Girija Goyal and Glenn Dranoff, MD, PhD, Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School |
|
IL-10 Elicits IFN-γ-Dependent Tumor Immune Intermediate TNFα Levels are Optimal in Mycobacterial Infection
A Review of Tobin, D.M., et al. Host genotype-specific therapies can optimize the Inflammatory response to mycobacterial infections. Cell (148):434-446, 2012.
Reviewed by Rachael A. Clark, MD, PhD, Department of Dermatology, Brigham and Women’s Hospital |
|
Hope for Malaria: PD-L1 and LAG-3 Blockade Clears Plasmodium Infection
A Review of Butler, N.S., et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nature Immunology (13):188-195, 2012.
Reviewed by Rachael A. Clark, MD, PhD, Department of Dermatology, Brigham and Women’s Hospital |
|
Why Do Patients With X-linked Lympoproliferative Disease Succumb to EBV but not Other Viruses?
A Review of Palendira, U. et al. Molecular Pathogenesis of EBV Susceptibility in XLP as Revealed by Analysis of Female Carriers with Heterozygous Expression of SAP. PLOS Biology. 9: e100187, 2011.
Reviewed by Michelle L. Hermiston, MD, PhD, University of California San Francisco |
|
Now You See Them, Now You Don’t: CD4+ T Cells in Acute and Chronic Hepatitis C Infection
A Review of zur Wiesch, J., et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J. Exp. Med, 209: 61-75, 2012.
Reviewed by Michelle L. Hermiston, MD, PhD, University of California San Francisco |
|
Adding New Dimensions to Flow Cytometry
A Review of Newell EW, Sigal N, Bendall SC, Nolan GP and Davis MM. Cytometry by Time-of-Flight Shows Combinatorial Cytokine Expression and Virus-Specific Cell Niches within a Continuum of CD8+ T Cell Phenotypes. Immunity. 36, 142-152, 2012.
Reviewed by Sarah Henrickson MD/PhD Children’s Hospital Boston and Harvard Medical School |
|
Crowdsourcing the Immune Response
A Review of Han Q, Bagheri N, Bradshaw EM, Hafler DA, Lauffenburger DA and JC Love. Polyfunctional responses by human T cells result from sequential release of cytokines. PNAS. 109, 1607-1612, 2012.
Reviewed by Sarah Henrickson MD/PhD Children’s Hospital Boston and Harvard Medical School |
|
|
Click here to send your comments and suggestions for future Translational Immunology Updates. |
|
A network made up of 66 interdisciplinary clinical immunology centers.
The global leader in immunology education, supporting basic & clinical scientists to perform the best research, create new tools and provide new insights.
A federation structure expands the outreach potential for each of the 52 Member Societies.
